// App-Quantinova.ai

279 ⋆ : Radiologic progression in primary sclerosing cholangitis (PSC) by two‐dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial

Researchers

Presenter

  • Andrew J. Muir

Principal Investigators

  • Elmira Hassanzadeh

  • V. Anik Sahni

  • Nisha Sainani

  • Mitchell L. Shiftman

  • Dora Ding

  • Catherine Jia

  • Bryan J. McColgan

  • Robert P. Myers

  • Mani Subramanian

  • John G. McHutchison

  • Zachary D. Goodman

  • Bertus Eksteen

  • Michael P. Manns

  • Cynthia Levy

  • Christopher L. Bowlus

  • Roger W. Chapman

  • Clare Tempany-Afdhal

Medical Centers

  • Duke Clinical Research Institute, Durham, NC

  • Brigham and Woma-s Hospital, Department of Pathology, Harvard Medical School, Boston, MA

  • Liver Institute of Virginia, Richmond, VA

  • Gilead Sciences, Inc., Foster City, CA

  • Inova Fairfax Hospital, Falls Church, VA

  • University of Calgary, Calgary, AB, Canada

  • Hannover Medical School, Hannover, Germany

  • University of Miami, Miami, FL

  • University of California, San Francisco, CA

  • Oxford University, Oxford, United Kingdom

Locations

  • United States

  • Canada

  • Germany

  • United Kingdom

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

Disease

  • Primary sclerosing cholangitis

  • Portal Hypertension

  • Hepatic fibrosis

  • Hypertension

  • Ascending cholangitis

Biomarkers

  • Alkaline phosphatase

Drug/Treatment

  • Alkaline phosphatase

  • Simtuzumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Prospective

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved